1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Ancora Pharmaceuticals Inc. - Product Pipeline Review - 2013

Ancora Pharmaceuticals Inc. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

Ancora Pharmaceuticals Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Ancora Pharmaceuticals Inc. - Product Pipeline Review - 2013” provides data on the Ancora Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ancora Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ancora Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ancora Pharmaceuticals Inc. - Brief Ancora Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ancora Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ancora Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ancora Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ancora Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ancora Pharmaceuticals Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ancora Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ancora Pharmaceuticals Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ancora Pharmaceuticals Inc. and identify potential opportunities in those areas.

Table Of Contents

Ancora Pharmaceuticals Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Ancora Pharmaceuticals Inc. Snapshot 4
Ancora Pharmaceuticals Inc. Overview 4
Key Information 4
Key Facts 4
Ancora Pharmaceuticals Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Ancora Pharmaceuticals Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Ancora Pharmaceuticals Inc. - Pipeline Products Glance 9
Ancora Pharmaceuticals Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Ancora Pharmaceuticals Inc. - Drug Profiles 11
Vaccine For Burkholderia 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Vaccine For Candida 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Vaccine For Enterococcus 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Vaccine For Moraxella catarrhalis 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Vaccine For Pseudomonas 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Vaccine For Staphylococcus 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Ancora Pharmaceuticals Inc. - Pipeline Analysis 17
Ancora Pharmaceuticals Inc. - Pipeline Products by Therapeutic Class 17
Ancora Pharmaceuticals Inc. - Pipeline Products By Target 18
Ancora Pharmaceuticals Inc. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21



List of Tables

Ancora Pharmaceuticals Inc., Key Information 4
Ancora Pharmaceuticals Inc., Key Facts 4
Ancora Pharmaceuticals Inc. - Pipeline by Indication, 2013 6
Ancora Pharmaceuticals Inc. - Pipeline by Stage of Development, 2013 7
Ancora Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2013 8
Ancora Pharmaceuticals Inc. - Preclinical, 2013 9
Ancora Pharmaceuticals Inc. - Discovery, 2013 10
Ancora Pharmaceuticals Inc. - Pipeline By Therapeutic Class, 2013 17
Ancora Pharmaceuticals Inc. - Pipeline By Target, 2013 18



List of Figures

Ancora Pharmaceuticals Inc. - Pipeline by Indication, 2013 6
Ancora Pharmaceuticals Inc. - Pipeline by Stage of Development, 2013 7
Ancora Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2013 8
Ancora Pharmaceuticals Inc. - Pipeline By Therapeutic Class, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.